See the DrugPatentWatch profile for Ubrelvy
Ubrelvy (ubrogepant) is a prescription medication used to treat acute migraine attacks. As of December 2023, there is no generic version of Ubrelvy available in the United States [1]. Ubrelvy is manufactured by AbbVie [2].
What is the typical cost of Ubrelvy?
The cost of Ubrelvy can vary significantly based on insurance coverage, pharmacy, and dosage. Without insurance, a 30-day supply can cost upwards of \$1,000 [3]. However, patients with commercial drug insurance may be eligible for a savings program that can reduce out-of-pocket costs to as low as \$10 per prescription [4].
When can a generic version of Ubrelvy be expected?
The patent exclusivity for Ubrelvy is a key factor in determining when a generic version might become available. According to DrugPatentWatch.com, the earliest patent expiry related to Ubrelvy is in 2031, with subsequent patents extending further [5]. Generics can typically enter the market after patent protection expires, provided all regulatory approvals are obtained.
How does Ubrelvy work for migraines?
Ubrelvy belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain and inflammation [1].
Are there alternatives to Ubrelvy for migraine treatment?
Other acute migraine treatments are available, including triptans and other CGRP antagonists. The choice of treatment often depends on individual patient factors, including the severity of migraines, other medical conditions, and previous treatment responses [6].